The need for cGMP DNA at affordable prices is increasing as more DNA-based medicines are entering the clinic.
Cytogenix has US and worldwide patent applications pending which describe a process for producing a version of DNA for use in gene therapy and in novel DNA vaccines. The process yields material that is an exact copy of a gene sequence from a traditional plasmid with a modified backbone.
CytoGenix has recently demonstrated that synDNA™ vaccines are highly immunogenic and can elicit both humoral and cellular immune responses. The synDNA™ material can be rapidly produced with process control that mimics the chemistry associated with small molecule production. Since no bacteria are used in the production of synDNA™, the burden of contamination from endotoxin, genomic DNA and adventitious viruses is virtually eliminated. The DNA vaccine results indicate the potential for uses of synDNA™ in other DNA-based medicines.
CytoGenix scientists will consult with the client's scientists to establish optimal starting material (template) configuration. The goal is to ship material in thirty (30) days from receipt of qualified starting material. Once a batch of synDNA™ has been made, subsequent batches from the same starting material can be made and shipped within one week.
Production of synDNA™ is provided under a Service contract that includes mutual confidentiality clauses. CytoGenix proprietary technology will be used to produce synDNA™ versions of the clients starting material only. Any other use by CytoGenix or the client is subject to other arrangements.
CytoGenix guarantees client satisfaction.
